Robot-picked raspberries, COVID-19 vaccines, Portugal and graphene: read our newsletter
Robot-picked raspberries are now in the shops, thanks to Fieldwork Robotics, featured in our latest newsletter. There are also updates on TVG, Portugal and a look at graphene.
Read moreBeyond Venture Funding: join our event with Williams Advanced Engineering on 17 May
Frontier IP is teaming up with Williams Advanced Engineering to explore alternatives to traditional venture capital approaches to supporting early-stage technology companies. The online event is at 3.00pm on 17 May.
Read moreHalf year results: pre-tax profits rise by 239 per cent to £10.3 million
Highlights for the six months to December included the float of Exscientia for a value of $2.9 billion. After the period end, we sold 25 per cent of our stake for £6.1 million.
Read moreFrontier IP raises further £3.2 million after selling more Exscientia shares
Most recent sales takes total net proceeds raised from Exscientia holding to £6.1 million. Following the sales, we retain 1,173,600 shares in the company. Learn more from Chief Executive Neil Crabb’s interview with Proactive London
Read moreCambridge Raman Imaging gains grant to transform cancer diagnosis and treatment
Portfolio company is coordinating CHARM, a pan-European project set to receive €3.3 million to develop low-cost, high-speed medical imaging technology for cancer diagnosis and treatment.
Read moreFrontier IP sells part of stake in Exscientia
Group’s net proceeds of approximately $4 million following sale of 183,901 shares for an average price of $21.68 per ADS.
Read moreFrontier IP: anticipates first half results ahead of management expectations
The Group has enjoyed strong progress for the half year to 31 December 2021 and has started programme to sell part of its Exscientia holding. Read the trading update here.
Read moreCelerum launches first product using AI to improve logistics
Portfolio company Celerum has launched Truck Logistics System, its first commercial software based on novel technology inspired by nature. The product has also won its first customer.
Read moreTVG next-generation COVID-19 vaccine achieves significant milestone
Pre-clinical trial data for The Vaccine Group’s Covid-19 vaccine have demonstrated the potential for broad immunity against current and future variants of Sars-CoV-2.
Read more“For us, it is fantastic when you see a product getting deployed or out there.”
Chief Executive Neil Crabb discusses commercialisation, the role of science and technology in sustainability and much more in this interview with the British Embassy, Lisbon, at Web Summit 2021.
Read more